Incyte(US:INCY)2026-02-10 14:02Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $1.51 billion, a 28% increase year-over-year, while full-year revenues totaled $5.14 billion, up 21% from the previous year [5][31] - Net sales for Q4 were $1.22 billion, representing a 20% increase year-over-year, and full-year net sales were $4.35 billion, also up 20% year-over-year [6][31] - R&D expenses for Q4 were $611 million, a 31% increase from the prior year, with full-year R&D expenses at $2.05 billion [31] - SG&A expenses for Q4 were $390 million, increasing 19% year-over-year, with full-year SG&A expenses at $1.38 billion, up 11% year-over-year [31] Business Line Data and Key Metrics Changes - Core business sales excluding Jakafi totaled $1.26 billion in 2025, a 53% increase compared to 2024, with significant contributions from OPZELURA, Niktimvo, and MONJUVI [6][10] - Jakafi sales in Q4 were $828 million, a 7% increase year-over-year, with full-year sales at $3.093 billion, an 11% increase [7] - OPZELURA's Q4 net sales were $207 million, up 28%, with full-year sales at $678 million, a 33% increase [9] - Hematology and oncology product sales in Q4 were $187 million, up 121% year-over-year, with full-year sales at $583 million, an 83% increase [10] Market Data and Key Metrics Changes - The U.S. market for OPZELURA in atopic dermatitis and vitiligo is expanding, with pediatric launches contributing to a strong start, annualizing around $30 million [9][46] - The international sales for OPZELURA in vitiligo doubled to $130 million in 2025, with expectations for continued growth [9] - The hematology and oncology business is projected to generate $800 million-$880 million in 2026, representing a 40%-50% increase compared to 2025 [13] Company Strategy and Development Direction - The company aims to transition its core business and pipeline, with multiple assets moving from early to late-stage development, targeting MPNs, pancreatic cancer, colorectal cancer, and hidradenitis suppurativa [4][5] - The long-term goal is to nearly double the size of the core business excluding Jakafi by 2030, with significant growth expected from upcoming product launches [10][13] - The company is focused on expanding its pipeline with 14 pivotal trials across seven assets by the end of 2026, indicating a robust growth strategy [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting a strong foundation for an inflection point in 2026 and beyond [5][6] - The company anticipates continued revenue growth driven by strong commercial performance and an increase in milestone and contract revenue [5][6] - Management emphasized the importance of execution in orchestrating product launches and managing multiple Phase III trials [35] Other Important Information - Regulatory applications for Jakafi XR, OPZELURA, and povorcitinib were submitted on time, enhancing visibility into the company's growth profile [5][6] - The company is exploring business development opportunities to extend and strengthen its core, with a focus on strategic fit and potential for durable revenue [15] Q&A Session Summary Question: Thoughts on CALR pivotal programs and dosing strategies - Management is discussing dosing strategies with the FDA and is confident in their approach to address differential potency across mutations [39][40] Question: OPZELURA uptake and modeling sales - The AD business is growing at nearly 20% year-over-year, with significant contributions from pediatric launches and international markets [45][46] Question: MONJUVI's opportunity in front-line DLBCL - MONJUVI is positioned as an addition to R-CHOP, with a focus on addressing a broader patient population and competitive PFS benefits [52][54] Question: OPZELURA in prurigo nodularis and FDA recommendations - The FDA recommended an additional trial for OPZELURA in PN due to mixed results from previous studies, with no implications for HS [64][66] Question: mCALR bispecific and V617F program conviction - The mCALR bispecific program is accelerating, with a focus on differentiating it from current programs, while the V617F program is expected to generate promising data [73][75]